Literature DB >> 33692776

TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation.

Yong Shi1,2,3,4,5, Wantong Su1,2,3,4,5, Lei Zhang1,2,3,4,5, Chengyu Shi1,2,3,4,5, Jinren Zhou1,2,3,4,5, Peng Wang1,2,3,4,5, Hao Wang1,2,3,4,5, Xiaoli Shi1,2,3,4,5, Song Wei1,2,3,4,5, Qi Wang1,2,3,4,5, Johan Auwerx6, Kristina Schoonjans6, Yue Yu1,2,3,4,5, Rui Pan1, Haoming Zhou1,2,3,4,5, Ling Lu1,2,3,4,5.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease associated with dysregulation of liver metabolism and inflammation. G-protein coupled bile acid receptor 1 (TGR5) is a cell surface receptor that is involved in multiple metabolic pathways. However, the functions of TGR5 in regulating macrophage innate immune activation in NASH remain unclear. Here, we found that TGR5 expression was decreased in liver tissues from humans and mice with NASH. Compared to wild type (WT) mice, TGR5-knockout (TGR5-/-) mice exhibited exacerbated liver damage, increased levels of proinflammatory factors, and enhanced M1 macrophage polarization. Moreover, TGR5 deficiency facilitated M1 macrophage polarization by promoting NLRP3 inflammasome activation and caspase-1 cleavage. Taken together, our findings revealed that TGR5 signaling attenuated liver steatosis and inflammation and inhibited NLRP3-mediated M1 macrophage polarization in NASH.
Copyright © 2021 Shi, Su, Zhang, Shi, Zhou, Wang, Wang, Shi, Wei, Wang, Auwerx, Schoonjans, Yu, Pan, Zhou and Lu.

Entities:  

Keywords:  G protein-coupled bile acid receptor 1; NLRP3 inflammasome; inflammation; macrophages; nonalcoholic steatohepatitis

Year:  2021        PMID: 33692776      PMCID: PMC7937818          DOI: 10.3389/fimmu.2020.609060

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  58 in total

1.  Identification of membrane-type receptor for bile acids (M-BAR).

Authors:  Takaharu Maruyama; Yasuhisa Miyamoto; Takao Nakamura; Yoshitaka Tamai; Hiromasa Okada; Eiji Sugiyama; Tatsuji Nakamura; Hiraku Itadani; Kenichi Tanaka
Journal:  Biochem Biophys Res Commun       Date:  2002-11-15       Impact factor: 3.575

Review 2.  Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.

Authors:  Maria Reich; Caroline Klindt; Kathleen Deutschmann; Lina Spomer; Dieter Häussinger; Verena Keitel
Journal:  Dig Dis       Date:  2017-03-01       Impact factor: 2.404

3.  Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Authors:  Zobair M Younossi; Rohit Loomba; Quentin M Anstee; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Zachary D Goodman; Naga P Chalasani; Kris V Kowdley; Jacob George; Keith Lindor
Journal:  Hepatology       Date:  2018-07       Impact factor: 17.425

4.  Thioredoxin-interacting protein links oxidative stress to inflammasome activation.

Authors:  Rongbin Zhou; Aubry Tardivel; Bernard Thorens; Inpyo Choi; Jürg Tschopp
Journal:  Nat Immunol       Date:  2009-12-20       Impact factor: 25.606

5.  Plasma membrane-bound G protein-coupled bile acid receptor attenuates liver ischemia/reperfusion injury via the inhibition of toll-like receptor 4 signaling in mice.

Authors:  Haojun Yang; Haoming Zhou; Lin Zhuang; Johan Auwerx; Kristina Schoonjans; Xuehao Wang; Cheng Feng; Ling Lu
Journal:  Liver Transpl       Date:  2017-01       Impact factor: 5.799

6.  The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain.

Authors:  Verena Keitel; Boris Görg; Hans J Bidmon; Irina Zemtsova; Lina Spomer; Karl Zilles; Dieter Häussinger
Journal:  Glia       Date:  2010-11-15       Impact factor: 7.452

7.  Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice.

Authors:  Kouichi Miura; Ling Yang; Nico van Rooijen; David A Brenner; Hirohide Ohnishi; Ekihiro Seki
Journal:  Hepatology       Date:  2013-02       Impact factor: 17.425

8.  Expression and function of the bile acid receptor TGR5 in Kupffer cells.

Authors:  Verena Keitel; Markus Donner; Stefanie Winandy; Ralf Kubitz; Dieter Häussinger
Journal:  Biochem Biophys Res Commun       Date:  2008-05-09       Impact factor: 3.575

9.  Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.

Authors:  Susannah D Brydges; Lori Broderick; Matthew D McGeough; Carla A Pena; James L Mueller; Hal M Hoffman
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

10.  Adipokines and cytokines in non-alcoholic fatty liver disease.

Authors:  M H Jarrar; A Baranova; R Collantes; B Ranard; M Stepanova; C Bennett; Y Fang; H Elariny; Z Goodman; V Chandhoke; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2007-12-10       Impact factor: 8.171

View more
  12 in total

Review 1.  Understanding the cellular interactome of non-alcoholic fatty liver disease.

Authors:  Sebastian J Wallace; Frank Tacke; Robert F Schwabe; Neil C Henderson
Journal:  JHEP Rep       Date:  2022-06-15

Review 2.  Discovery of farnesoid X receptor and its role in bile acid metabolism.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Mol Cell Endocrinol       Date:  2022-03-11       Impact factor: 4.369

3.  Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease.

Authors:  Stefano Fiorucci; Pasquale Rapacciuolo; Bianca Fiorillo; Rosalinda Roselli; Silvia Marchianò; Cristina Di Giorgio; Martina Bordoni; Rachele Bellini; Chiara Cassiano; Paolo Conflitti; Bruno Catalanotti; Vittorio Limongelli; Valentina Sepe; Michele Biagioli; Angela Zampella
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

4.  Reversal of NAFLD After VSG Is Independent of Weight-Loss but RYGB Offers More Efficacy When Maintained on a High-Fat Diet.

Authors:  Ankita Srivastava; Matthew Stevenson; Jenny Lee; Christopher Hall; Thomas Palaia; Chaohui Lisa Zhao; Raymond Lau; Collin Brathwaite; Louis Ragolia
Journal:  Obes Surg       Date:  2022-04-14       Impact factor: 3.479

Review 5.  Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.

Authors:  Baoyi Guan; Jinlin Tong; Haiping Hao; Zhixu Yang; Keji Chen; Hao Xu; Anlu Wang
Journal:  Acta Pharm Sin B       Date:  2021-12-22       Impact factor: 14.903

Review 6.  Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases.

Authors:  Fangling Zhang; Xiaolin Xiao; Yong Li; Hefei Wu; Xinyu Deng; Yinxiao Jiang; Wenwen Zhang; Jian Wang; Xiao Ma; Yanling Zhao
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 7.  Macrophage Polarization and Its Role in Liver Disease.

Authors:  Cheng Wang; Cheng Ma; Lihong Gong; Yuqin Guo; Ke Fu; Yafang Zhang; Honglin Zhou; Yunxia Li
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

Review 8.  Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Eunju Park; Jin-Ju Jeong; Sung-Min Won; Satya Priya Sharma; Yoseph Asmelash Gebru; Raja Ganesan; Haripriya Gupta; Ki Tae Suk; Dong Joon Kim
Journal:  Cells       Date:  2021-10-02       Impact factor: 6.600

Review 9.  The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  John P Thomas; Dezso Modos; Simon M Rushbrook; Nick Powell; Tamas Korcsmaros
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

Review 10.  Physiological Role of Bile Acids Modified by the Gut Microbiome.

Authors:  Yoshimitsu Kiriyama; Hiromi Nochi
Journal:  Microorganisms       Date:  2021-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.